A new oral therapy for people with type 2 diabetes could soon be available in the UK after Jansse, the European subsidiary of Johnson and Johnso, submitted its investigational type 2 diabetes medication, canagliflozi, to European regulators for approval.
The drug is part of a new class of diabetes medicines called sodium glucose co-transporter 2 (SGLT2) inhibitors, which work by blocking the reabsorption of glucose by the kidney to increase glucose excretion and reduce blood glucose levels .
Earlier this week, Janssen submitted a Marketing Authorisation Application to the European Medicines Agency (EMA) for the once-daily drug treatment, which was backed by data from the global phase III clinical trial programme – one of the largest randomised clinical studies in the field of type 2 diabetes .
Results from some of the phase III studies, presented by Janssen at a American Diabetes Association meeting earlier this month, demonstrated substantial and sustained glycemic improvements and showed canagliflozin’s potential as a monotherapy, compared to the current standard treatments of Januvia and Amaryl (glimepiride).
If approved by the EMA, canagliflozin will go up against Forxiga (dapagliflozin), a rival SGLT2 from AstraZeneca/Bristol-Myers Squibbs which is expected to receive full European approval before the end of next month.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Coronavirus: UK instructed to stay at home this weekend

Health Secretary Matt Hancock has said that staying at home this weekend…

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…